Aclaris Therapeutics ROE 2025

Aclaris Therapeutics Aktienanalyse

What does Aclaris Therapeutics do?

Aclaris Therapeutics Inc was founded in 2012 and is based in Wayne, Pennsylvania. The company focuses on the development and marketing of innovative solutions for the treatment of skin problems and other diseases that significantly impact the quality of life of those affected. Aclaris' business model is based on the research and development of new therapies that address various medical problems and conditions. The company employs a combination of internal research projects and the acquisition of promising products and pipeline assets from third-party companies. Aclaris is divided into different business segments that focus on various medical issues and conditions. One important area is dermatology, where the company has developed several innovative products and therapies. This includes RHOFADE® (Oxymetazoline Hydrochloride), a topical medication for the treatment of rosacea. The novel product A-101, used for the treatment of seborrheic keratosis, has also been established in the market. In the field of oncological dermatology, Aclaris has a promising pipeline focused on the development of drugs for the treatment of actinic keratosis, basal cell carcinoma, squamous cell carcinoma, and melanoma. The company collaborates closely with scientists and research institutions to develop innovative solutions that can revolutionize the pharmaceutical market. Another area that Aclaris focuses on is immunology, including the development of new therapies for the treatment of inflammatory diseases such as alopecia areata, an autoimmune disease that causes hair loss. Aclaris has already made significant progress in this area and is conducting clinical studies to demonstrate the effectiveness of its products in treating this condition. In addition to the development of innovative therapies, Aclaris also collaborates closely with other companies and research institutions to develop platform technologies that can accelerate and simplify the development of new drugs. This includes state-of-the-art analytical methods and the development of new molecules that specifically target certain diseases. Aclaris' business model has proven successful in recent years. The company combines internal research projects with the acquisition of promising pipeline assets from third-party companies to expand its portfolio and pipeline. This approach allows Aclaris to quickly respond to changing market conditions and patient needs, positioning themselves as a leading player in the pharmaceutical market. Aclaris' products have already improved many lives and successfully treated numerous patients with various medical problems. The company aims to achieve sustainable improvement in the quality of life of patients and continuously develop new innovative solutions to secure a leading position in the highly competitive pharmaceutical market. Aclaris Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Aclaris Therapeutics's Return on Equity (ROE)

Aclaris Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Aclaris Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Aclaris Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Aclaris Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Aclaris Therapeutics stock

What is the ROE (Return on Equity) of Aclaris Therapeutics this year?

The ROE of Aclaris Therapeutics this year is -0.56 undefined.

How has the Return on Equity (ROE) of Aclaris Therapeutics developed compared to the previous year?

The ROE of Aclaris Therapeutics has increased by 27.99% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Aclaris Therapeutics?

A high ROE indicates that Aclaris Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Aclaris Therapeutics?

A low ROE can indicate that Aclaris Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Aclaris Therapeutics affect the company?

A change in ROE (Return on Equity) of Aclaris Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Aclaris Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Aclaris Therapeutics?

Some factors that can influence Aclaris Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Aclaris Therapeutics pay?

Over the past 12 months, Aclaris Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aclaris Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aclaris Therapeutics?

The current dividend yield of Aclaris Therapeutics is .

When does Aclaris Therapeutics pay dividends?

Aclaris Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aclaris Therapeutics?

Aclaris Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aclaris Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aclaris Therapeutics located?

Aclaris Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aclaris Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aclaris Therapeutics from 1/17/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/17/2025.

When did Aclaris Therapeutics pay the last dividend?

The last dividend was paid out on 1/17/2025.

What was the dividend of Aclaris Therapeutics in the year 2024?

In the year 2024, Aclaris Therapeutics distributed 0 USD as dividends.

In which currency does Aclaris Therapeutics pay out the dividend?

The dividends of Aclaris Therapeutics are distributed in USD.